| Date | Quarter | Session | EPS (est → actual) | Revenue (est → actual) |
|---|---|---|---|---|
| Nov 2, 2026Next | Q3 2026 | Before market open | 1.52 | 2.32 B |
Sep 1, 2026
Zoetis (ZTS) emerges from decent value screen with low P/E, high profitability, and strong returns. Growth moderates, leverage noted. Learn more.
Aug 30, 2026
PAHCâs Zoetis MFA acquisition boosts animal-health growth via vaccines and companion animals. Click for more on PAHC stock.
Aug 27, 2026
Phibro Animal Health (NASDAQ:PAHC) reported record fiscal 2026 sales and a sharp increase in adjusted EBITDA, supported by growth in its Animal Health and Mineral Nutrition businesses, the integration of its acquired Zoetis medicated feed additive portfolio, and operational initiatives under its Phi
Aug 25, 2026
TD Cowen analyst Steve Scala maintains Zoetis (NYSE:ZTS) with a Buy and lowers the price target from $104 to $94.
Aug 24, 2026
The timing of Zoetis Inc.’s (NYSE:ZTS) latest regulatory win is particularly relevant for shareholders. Just one week after the animal-health company reported a 7% decline in U.S. revenue and an 11% drop in domestic companion-animal product sales, Simparica Trio received Emergency Use Authorization to treat New World screwworm infestations in dogs and puppies. The treatment […]
Aug 23, 2026
Zoetis Inc. (NYSE:ZTS) entered 2026 as a leader in animal health, but its latest earnings show that even a strong market position cannot fully insulate the company from weaker consumer demand. Fiscal Q2 2026 revenue remained flat at $2.5 billion and declined 1% on an organic operational basis, as pressure in the U.S. companion-animal market […]
Aug 20, 2026
Stifel analyst Jonathan Block maintains Zoetis (NYSE:ZTS) with a Hold and lowers the price target from $85 to $80.
Aug 19, 2026
Zoetis stock has had a tough run over the last few years, yet the current valuation checks suggest the shares may now be pricing in a lot of that bad news. After a prolonged slide, the question is whether the current market price properly reflects Zoetis' earnings power and risks. Over the past 5 years, Zoetis shareholders have seen the share price decline about 61.8%, which points to a significant reset in expectations. Recent investor focus is on how competition and softer pet care...
Zoetis recently received an Emergency Use Authorization from the U.S. FDA for its Simparica Trio chewable to treat life-threatening New World screwworm infestations in dogs and puppies, while also appointing experienced healthcare executive Jay Saccaro as its new Chief Financial Officer and Chief Operating Officer. At the same time, Zoetis lowered its full-year 2026 revenue and earnings guidance, signaling a more cautious outlook even as it expands the clinical reach of one of its flagship...
Aug 18, 2026
Zoetis (NYSE:ZTS) is an animal health company. Michael Burry is long the stock, several media outlets reported, citing his Substack disclosures. The stock is down about 40% so far this year. Let’s break down whether it’s worth buying. Why Burry Likes It Burry’s pitch is simple. Zoetis has dropped more than 70% from its 2021 […]
Despite aggressive competitor promotions, Zoetis protects industry-leading profitability. Click here to find out why ZTS stock is a Buy.
Aug 16, 2026
Zoetisâ mixed Q2 earnings and lowered guidance hit margin of safety, but long-term upside remains. Click for more on ZTS stock.
Aug 15, 2026
Zoetis delivered flat revenue in Q2, missing Wall Street expectations, while its adjusted earnings per share slightly exceeded consensus. The market’s positive reaction was underpinned by management’s acknowledgment of intensifying competitive pressures in key Companion Animal categories and ongoing declines in U.S. veterinary clinic visits. CEO Kristin Peck noted, “Veterinary clinic visits declined across markets, extending a multiyear trend that has occurred alongside price increases that have
Aug 14, 2026
Polen Capital Management Llc released its “Polen Focus Growth Strategy” Q2 2026 investor letter. A copy of the letter can be downloaded here. Polen Focus Growth returned 6.33% (net of fees) in the second quarter of 2026, significantly underperforming the Russell 1000 Growth Index’s 16.74% gain, as the market rally remained narrowly focused on AI […]
Zoetis (ZTS) trades at 12x forward earnings with a ~3% yield after a big drawdownâsee why its margins, buybacks, and value setup make it a Buy. Read the full analysis here.
